Cojutti Pier Giorgio, Fornaro Giacomo, Gatti Milo, Rinaldi Matteo, Gaibani Paolo, Giannella Maddalena, Pea Federico, Viale Pierluigi
SSD Clinical Pharmacology, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy.
Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy.
Infect Dis Rep. 2022 Jan 21;14(1):88-92. doi: 10.3390/idr14010010.
Bacteremia and ventilator-associated pneumonia due to a pan-resistant strain co-producing KPC and OXA-48 carbapenemases was successfully treated in a COVID-19 critically ill patient with a combination therapy of a high-dose continuous infusion of meropenem (up to 3 g every 6 h, daily) plus fosfomycin (up to 24 g/daily) that was guided by real-time therapeutic drug monitoring. Clinical pharmacological advice was helpful in maximizing, over time, the pharmacodynamic target attainment of both antibiotics.
一名新冠肺炎重症患者感染了同时产KPC和OXA - 48碳青霉烯酶的全耐药菌株，导致菌血症和呼吸机相关性肺炎，通过高剂量持续输注美罗培南（每6小时高达3克，每日）联合磷霉素（每日高达24克）的联合治疗，并在实时治疗药物监测的指导下成功治愈。随着时间的推移，临床药理学建议有助于使两种抗生素的药效学目标达成最大化。
